TMI most commonly stands for “too much information,” a casual expression people use when someone shares details that are overly personal, graphic, or uncomfortable. You’ve probably heard it in conversation or seen it in text messages when someone overshares about a medical procedure, a bathroom incident, or the intimate details of a relationship. It’s a lighthearted way to signal that a boundary has been crossed, without making things more awkward than they already are.
In medical settings, TMI has a completely different meaning: Total Marrow Irradiation, a targeted radiation technique used before bone marrow transplants. If you came across “TMI” in a medical context and want to understand it, read on.
TMI as Slang: Too Much Information
“TMI” entered mainstream slang in the late 1990s and early 2000s as internet culture popularized abbreviations. It works both as a spoken phrase (“that’s TMI”) and as a texting shorthand. The expression is almost always used reactively, after someone has already said something uncomfortable, rather than as a preemptive warning. It carries a tone that’s more playful than genuinely offended.
You’ll see it used in a few common situations: when someone describes bodily functions in detail, when a friend shares too much about their love life, or when a coworker brings up a personal health issue at the lunch table. It can also be used self-awarely, as in “this might be TMI, but…” before launching into something personal anyway.
TMI in Medicine: Total Marrow Irradiation
In oncology, TMI refers to Total Marrow Irradiation, a radiation therapy technique that targets the entire skeleton while minimizing damage to surrounding organs. It was developed as a safer alternative to total body irradiation (TBI), the traditional approach used to prepare patients for bone marrow or stem cell transplants. Where TBI floods the whole body with radiation, TMI focuses the dose on the bone marrow itself.
The goal is twofold: destroy cancerous cells living in the bone marrow and suppress the immune system enough so the body will accept donor stem cells. TMI is used for blood cancers including acute myeloid leukemia, acute lymphoblastic leukemia, multiple myeloma, myelodysplastic syndrome, and certain types of lymphoma. It’s particularly valuable for patients considered high-risk or who have relapsed after previous treatment, as well as older or frailer patients who might not tolerate full-body radiation.
How TMI Differs From Full-Body Radiation
The key advantage of TMI is organ sparing. Compared to traditional total body irradiation, TMI delivers roughly 55 to 60% less radiation to the lungs, 55 to 60% less to the liver, 55 to 60% less to the gastrointestinal tract, and 36 to 40% less to the kidneys. That reduction matters enormously for recovery and long-term health.
This precision also opens the door to dose escalation. Standard TBI protocols typically deliver between 2 and 12 Gy (the unit used to measure absorbed radiation), but because TMI spares so much healthy tissue, doctors can push doses up to 15 Gy or higher when needed to fight aggressive disease. Higher doses to the marrow can reduce the chance of relapse without the devastating side effects that would come from blasting the entire body at that level.
How the Treatment Is Delivered
TMI relies on advanced radiation technology that can shape beams precisely around the skeleton. Historically, most treatments have been delivered using helical tomotherapy machines, which can treat the full length of the body in a continuous sweep without repositioning the patient multiple times. More recently, centers have begun using a technique called VMAT (volumetric modulated arc therapy) on standard linear accelerators, making the treatment available at more hospitals.
Before treatment begins, patients undergo detailed CT scanning to map the entire skeleton. Multiple scans capture different breathing positions so the treatment plan can account for how organs shift during respiration. During each session, imaging is repeated to confirm the patient is positioned accurately, sometimes using cone-beam CT scans at different body regions along with X-ray verification of the spine.
A related variation called TMLI, or total marrow and lymphoid irradiation, extends the target area beyond the skeleton to include the lymph nodes, spleen, and liver. TMLI is typically used before donor transplants (allogeneic transplants) because irradiating the lymphoid tissue further suppresses the recipient’s immune system, reducing the risk that the body will reject the donor’s cells.
Side Effects and Outcomes
Because TMI spares critical organs, its side effect profile is notably milder than traditional full-body radiation. In a study of 142 patients treated with TMI, only one (0.7%) developed radiation-induced lung inflammation. No radiation-related kidney damage was observed. Hypothyroidism occurred in about 6% of patients, and cataracts developed in 7%, both of which are manageable long-term conditions. Keeping the average lung dose at 8 Gy or below was associated with significantly lower rates of pulmonary complications.
In terms of survival, a recent multicenter study with a median follow-up of about 19 months reported two-year overall survival of 71.7% and two-year disease-free survival of 60.0% for patients receiving TMI-based conditioning before a donor transplant. These patients had blood cancers, many of them high-risk or previously treated, so those numbers reflect a population that already faced difficult odds.
TMI remains a specialized procedure available primarily at major cancer centers, but its use is expanding as more hospitals adopt the technology needed to deliver it. For patients facing a stem cell transplant, it represents a meaningful step forward in reducing the toll that radiation takes on the body while still effectively targeting the disease.